Premium
ELISA ANTI‐HLA ANTIBODY SCREENING IDENTIFIES NON‐COMPLEMENT‐FIXING ANTIBODIES RESPONSIBLE FOR ACUTE GRAFT REJECTION. A CASE REPORT
Author(s) -
NanniCosta A.,
Scolari M. P.,
Iannelli S.,
Vangelista A.,
Buscaroli A.,
D'Arcangelo G. Liviano,
Buttazzi R.,
Sanctis L. B. de,
Todeschini P.,
Stefoni S.,
Bonomini V.
Publication year - 1996
Publication title -
international journal of immunogenetics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.41
H-Index - 47
eISSN - 1744-313X
pISSN - 1744-3121
DOI - 10.1111/j.1744-313x.1996.tb00011.x
Subject(s) - antibody , human leukocyte antigen , complement (music) , immunology , graft rejection , medicine , transplantation , antigen , biology , genetics , gene , phenotype , complementation
SUMMARY We report on a kidney transplant recipient experiencing an unexpected early acute vascular graft rejection. Retrospective analysis of patient serum samples, utilizing a new ELISA HLA screening technique, revealed that the rejection crisis and the subsequent graft loss were due to a pretransplant donor‐specific pre‐sensitization caused by a non‐complement‐fixing antibody of IgG2 class. The case illustrates the clinical significance of non‐complement‐fixing anti‐HLA antibodies. In addition it is shown that ELISA methods are suitable for detecting potentially harmful donor pre‐sensitization in waiting‐list patients not detectable by standard lymphocytotoxicity techniques. Hence ELISA could be an alternative to flow cytometry for this purpose. It is concluded that screening and cross‐matching techniques which detect non‐complement‐fixing anti‐HLA antibodies could improve graft outcome, and should form part of the immunological monitoring of kidney transplant waiting‐list patients.